Shimao Servs Hldgs (OTC:SHMSF) Stock, Quote.Headers.trade-ideas

Shimao Services Holdings Ltd is a property management and community living service provider in the PRC. The company operates in business in four segments namely property management services; community value-added services; value-added services to non-property owners and city services. It offers a wide range of property management services to property developers, property owners and residents. Its value-added services to non-property owners include sales office management services; preliminary planning and design consultancy services; and repair and maintenance services. It derives maximum revenue from Property management services.

SHIMAO SVCS HLDG LTD by Shimao Services Holdings Ltd.

Shimao Services Holdings Ltd

Barclays analyst Raimo Lenschow maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Equal-Weight and lowers the price target from $103 to $97.

News

Price Target

Analyst Ratings

PEGA

Barclays Maintains Equal-Weight on Pegasystems, Lowers Price Target to $97

WIIM

Seaboard shares are trading higher after the company reported a year-over-year increase in Q4 financial results.

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 15 years by 21.79% on an annualized basis producing an average annual return of 33.82%. Currently, Fair Isaac has a market capitalization of $44.07 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 15 years ago, it would be worth $7,951.87 today based on a price of $1802.79 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739546109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FICO

$100 Invested In Fair Isaac 15 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $119.48, after a 1.33% spike. Over the past month, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock increased by 66.46%, and in the past year, by 410.55%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1739546110_0.png" alt="Past Year Chart" />

<h3>Comparing Palantir Technologies P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Palantir Technologies has a lower P/E than the aggregate P/E of 648.56 of the Software industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739546110_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

PLTR

Price Over Earnings Overview: Palantir Technologies

WYNN

Wynn Resorts shares are trading higher after Mizuho raised its price target on the stock from $118 to $132.

Barclays analyst Balaji Prasad maintains Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) with a Overweight and lowers the price target from $26 to $24.

Barclays Maintains Overweight on Organon, Lowers Price Target to $24

NMRK

Newmark Group shares are trading higher after the company reported better-than-expected Q4 financial results.

Barclays analyst Tim Long maintains Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) with a Overweight and lowers the price target from $529 to $527.

Barclays Maintains Overweight on Motorola Solns, Lowers Price Target to $527

Barclays analyst Ryan Macwilliams maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Overweight and raises the price target from $38 to $48.

FROG

Barclays Maintains Overweight on JFrog, Raises Price Target to $48

A new <a href="https://dealtracker.viridianca.com/valuation-tracker-by-industry-sector/">valuation analysis</a> by Viridian Capital Advisors suggests that U.S. multi-state cannabis operators (MSOs) are trading at levels that indicate no expectation of federal rescheduling or 280E tax relief. The firm conducted a discounted cash flow (DCF) study of 15 cannabis companies, modeling a worst-case scenario where 280E remains indefinitely, growth slows and EBITDA margins peak in 2027 before declining. Despite the bleak outlook, market valuations remain slightly higher than the model predicts, though Viridian explicitly states that this does not indicate confidence in federal reform.
<h2 class="wp-block-heading">Valuation Analysis: The Worst-Case Scenario For Marijuana Stocks</h2>
Viridian built a DCF model assuming that MSO EBITDA multiples should be compressed under current market realities. The analysis factors in:
<ul>
<li>No repeal of 280E, meaning cannabis operators will continue facing high tax burdens.</li>
<li>Slowing revenue growth, peaking at 9.8% in 2027 before declining to 6% and then 5%.</li>
<li>Declining EBITDA margins, topping at 28.4% in 2027 before deterioration.</li>
<li>A 25% tax rate on gross profit, calculated at 1.5x EBITDA to reflect current taxation realities.</li>
<li>A required equity return of 18.8%, reflecting industry volatility and risk factors, including federal illegality and commoditization.</li>
<li>Debt rates at 15%, aligned with trading yields of the most creditworthy MSOs.</li>
</ul>
Based on these assumptions, Viridian calculated that 2024 EBITDA multiples should fall between 3.95x and 4.93x. Yet, as of February 7, 2025, the median EV/2024 EBITDA multiple across major MSOs stood at 5.49x. Nonetheless, Viridian notes that this does not reflect optimism for federal reform but rather other market factors that may be sustaining valuations.
<h3 class="wp-block-heading">The Companies Analyzed: Top MSOs, Mid-Tier Players And Regional Operators</h3>
Viridian examined a mix of top-tier MSOs, mid-sized operators and regionally focused cannabis companies, each facing unique market pressures. The study included:
<h4 class="wp-block-heading">Leading MSOs</h4>
<ul>
<li>Curaleaf Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)</li>
<li>Green Thumb Industries, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>)</li>
<li>Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>)</li>
<li>Verano Holdings Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>)</li>
<li>Cresco Labs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>)</li>
<li>TerrAscend Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTC">TSNDF</a>)</li>
</ul>
<h4 class="wp-block-heading">Mid-Tier MSOs And Vertically Integrated Operators</h4>
<ul>
<li>Ascend Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>)</li>
<li>AYR Strategies Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>)</li>
<li>The Cannabist Company (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTC">CBSTF</a>)</li>
<li>Jushi, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JUSHF#OTC">JUSHF</a>)</li>
<li>MariMed Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>)</li>
<li>Planet 13 Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNHF#OTC">PLNHF</a>)</li>
</ul>
<h4 class="wp-block-heading">Regional Players And Specialists</h4>
<ul>
<li>Cansortium, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TIUMF#OTC">TIUMF</a>)</li>
<li>Glass House Brands Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTC">GLASF</a>)</li>
<li>Grown Rogue International Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>)</li>
<li>Vireo Growth Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VREOF#OTC">VREOF</a>)</li>
</ul>
<h2 class="wp-block-heading">The Market&#8217;s Verdict: No Rescheduling Priced In</h2>
Despite some MSOs trading above the 4-5x EBITDA range derived from the DCF model, Viridian states: &#8220;The market is not assuming that 280E will be eliminated, or at least not in the next year.&#8221; This aligns with its broader conclusion: &#8220;Expectations of slowing growth and peaking margins are ingrained in valuations.&#8221;
Viridian makes it clear that while valuations are not as dire as the model suggests, they remain muted. A year ago, optimism about rescheduling, SAFE Banking and tax relief was higher. Today, MSOs trade at levels that suggest no expectation of federal reform in the near term. The slight premium in valuations over the worst-case scenario does not indicate confidence in federal action but rather other market factors, such as state-level growth potential or operational efficiencies.
<h2 class="wp-block-heading">Florida And Texas: The Only Growth Hope?</h2>
Viridian's 2027 growth peak of 9.8% seems tied to speculation about Florida and Texas opening up to adult-use markets. Trulieve, Verano and Cansortium stand to gain significantly if Florida legalizes recreational sales, while companies like Cresco, Green Thumb and Curaleaf could benefit from Texas expansion. However, Viridian does not suggest that federal reform is driving these expectations—rather, state-level catalysts are viewed as the only potential bright spots.
<h3 class="wp-block-heading">What&#8217;s Next?</h3>
With rescheduling uncertainty and no immediate policy relief expected, the U.S. cannabis industry remains in valuation limbo. While top-tier MSOs still command respectable multiples, smaller players face significant pressure. Investors appear cautiously pessimistic, not fully pricing in catastrophe but likely lacking confidence in swift federal action.
The key catalysts to watch include state-level adult-use legalization (Florida, Texas), potential movement on SAFE Banking and the long-delayed rescheduling decision. However, Viridian's analysis indicates that valuations are not reflecting hope for federal reform and that any potential upside is tied to state-driven growth and operational factors rather than expected policy changes.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43708331/robert-f-kennedys-confirmation-cannabis-advocates-question-his-new-vow-to-follow-the-science-on-marijuanas-harms">Robert F. Kennedy&#8217;s Confirmation: Cannabis Advocates Question His New Vow To &#8216;Follow The Science&#8217; On Marijuana&#8217;s Harms</a></li>
</ul>

Analyst Color

Cannabis

Small Cap Analysis

AAWH

AYRWF

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GLASF

GRUSF

GTBIF

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

MRMD

PLNHF

TCNNF

TIUMF

TSNDF

VREOF

VRNOF

Cannabis Stock Valuations Reflect No Expectation Of Federal Reform: Study

Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) plans to open approximately 500 new locations in the <a href="https://www.benzinga.com/topic/middle-east">Middle East over the next five years</a>.
This initiative is part of the Seattle-based company's strategy to bounce back from last year's difficulties, reported <a href="https://www.bloomberg.com/news/articles/2025-02-14/starbucks-to-open-500-stores-in-middle-east-in-next-five-years?sref=TBDibEcD">Bloomberg</a>.
A noticeable decline in sales followed widespread boycott calls on social media platforms. People alleged the company supported Israel in the <a href="https://www.benzinga.com/top-stories/23/12/36120927/starbucks-stock-sees-longest-losing-streak-ever-amid-boycotts-over-israel-palestine-war">conflict with Palestine</a>. Starbucks <a href="https://about.starbucks.com/press/2023/what-has-starbucks-said-about-the-conflict-in-israel-and-gaza/">denied</a> the claim. 
The coffee chain giant plans to create about 5,000 new jobs as part of its expansion. It&#8217;ll also bring the total number of stores in the Middle East to over 1,800.
The announcement comes as Brian Niccol, who took over as the CEO last year, aims to <a href="https://www.benzinga.com/news/24/10/41312974/starbucks-shifts-strategy-fewer-deals-more-focus-on-quality-coffee-and-holiday-favorites">reinforce Starbucks&#8217; premium image</a>.
Niccol&#8217;s plan to restore the company's identity as a community-focused coffeehouse includes taking into account the importance of comfortable seating and a clear separation between <a href="https://www.benzinga.com/news/24/09/40809142/brian-niccol-outlines-vision-to-reconnect-starbucks-with-community-coffeehouse-roots-on-his-2nd-day">"to-go" and "for-here" services</a>.
Related Read: <a href="https://www.benzinga.com/25/02/43651110/starbucks-faces-legal-action-over-alleged-discriminatory-hiring-practices">&#8216;Racism Has No Place in Missouri&#8217;: State Attorney General Sues Starbucks Over Hiring Policies</a>
Niccol, previously credited with revitalizing Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) and Taco Bell, owned by Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), is now Starbucks' fourth CEO in just two years. 
Starbucks has been reeling with declining sales as customers have voiced concerns about rising prices, slow app orders, and disappointing food offerings. 
To make matters worse, unionization efforts have gained momentum as employees express dissatisfaction with pay, benefits, and working conditions.
In response to the turnaround effort, the Starbucks reported first-quarter revenue of $9.4 billion and earnings of 69 cents per share, both <a href="https://www.benzinga.com/general/restaurants/25/01/43288533/starbucks-q1-earnings-revenue-beat-eps-beat-memberships-up-1-positive-response-to-turnaround-efforts">well above the consensus estimates</a>.
During the earnings call, Niccol highlighted the priority for international expansion as he mentioned that the company is actively looking for opportunities in <a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/43304077/starbucks-stock-is-rising-wednesday-whats-going-on-2">China to drive sales growth in the region</a>. 
The Starbucks CEO also stated that while the company plans to reduce the number of new store openings in 2025, he anticipates strong demand for additional locations in the long run.
Price Action: SBUX shares are trading higher by 0.46% at $112.91 at the last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43694382/consumer-giant-unilever-warns-on-slower-start-to-2025-ice-cream-spin-off-moves-forward-with-amsterdam-incorporation">Consumer Giant Unilever Warns On Slower Start To 2025, Ice Cream Spin-Off Moves Forward With Amsterdam Incorporation</a></li>
</ul>
Image: Shutterstock

SBUX

Starbucks Plans To Open 500 New Stores In Middle East- Report

Barclays analyst Brandt Montour maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Equal-Weight and lowers the price target from $162 to $151.

Barclays Maintains Equal-Weight on Hyatt Hotels, Lowers Price Target to $151

JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) with a Market Outperform and maintains $16 price target.

Reiteration

CVAC

JMP Securities Reiterates Market Outperform on CureVac, Maintains $16 Price Target

Barclays analyst Trevor Young maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Overweight and raises the price target from $235 to $243.

GDDY

Barclays Maintains Overweight on GoDaddy, Raises Price Target to $243

Macro Economic Events

Econ #s

Economics

Earlier Reported US Business Inventories (MoM) For Dec. -0.2% Vs 0.0% Est.; 0.1% Prior

Barclays analyst Julian Mitchell maintains Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) with a Overweight and raises the price target from $45 to $46.

Barclays Maintains Overweight on Vontier, Raises Price Target to $46

CAE shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

CRSP

CRISPR Therapeutics shares are trading higher after Evercore ISI upgraded the stock from In-Line to Outperform and raised its price target from $60 to $99. Also, Morgan Stanley raised its price target from $30 to $32.

Barclays analyst Julian Mitchell maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Equal-Weight and lowers the price target from $30 to $27.

Barclays Maintains Equal-Weight on Kennametal, Lowers Price Target to $27

Making a noteworthy insider sell on February 13, Donald J Klunk, Chief Accounting Officer at Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), is reported in the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001398659/000139865925000029//Archives/edgar/data/1398659/000139865925000029/0001398659-25-000029-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Klunk sold 4,136 shares of Genpact. The total transaction value is $226,942.
As of Friday morning, Genpact shares are down by 0.0%, currently priced at $55.54.
<h3>Discovering Genpact: A Closer Look</h3>
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
<h3>Genpact's Financial Performance</h3>
Revenue Growth: Genpact's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.62%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 35.63%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Genpact's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.75.
</li>
</ul>
Debt Management: Genpact's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: Genpact's P/E ratio of 19.49 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.1, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 13.1, Genpact demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001398659">Check Out The Full List Of Genpact's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Shimao Servs Hldgs

Shimao Servs Hldgs (OTC:SHMSF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga